Medtronic recently announced results from a subset analysis of the ABRE study showing an obesity paradox reflected in outcomes ...

October 28, 2024—Medtronic announced new long-term data from the SPYRAL HTN-ON MED clinical trial of the company’s Symplicity Spyral renal denervation (RDN) system. The findings show that patients who ...

The Affera mapping and ablation system with the Sphere-9 catheter [Images courtesy of Medtronic] Medtronic (NYSE:MDT) today said it received FDA approval for its Affera mapping and ablation system ...

Medtronic has issued a second alert letter to patients regarding shortened battery life of the MiniMed 600 and 700 series insulin pumps. The affected products include the MiniMed 630G, 670G, 770G ...

Medtronic MDT underwent analysis by 15 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The following table provides a quick overview of their recent ...

Copyright © 2024 MarketWatch, Inc. All rights reserved.

Medtronic plc added a second U.S. FDA pulsed field ablation (PFA) device approval to its scorecard with the agency’s greenlight for its Affera mapping and ablation system with the Sphere-9 catheter.

The Staff Selection Commission (SSC) has released the SSC CHSL Tier II 2024 exam city link for candidates appearing in the Combined Higher Secondary (10+2) Level Examination, 2024 (Tier-II).

Medtronic plc received U.S. FDA approval to undertake an early feasibility study of its dual-energy Affera cardiac ablation system in sustained ventricular tachycardia. Affera combines both ...

24, 2024 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced United States Food and Drug Administration (FDA) approval of the Affera™ Mapping and ...